Keros Therapeutics (KROS) Earnings Analysis
Keros Therapeutics (KROS) has no confirmed upcoming earnings date. Last quarter (2026-05-14) it missed with EPS -1.21 USD vs -0.92 USD est (-31.5%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -4.18.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does KROS next report earnings?
No confirmed upcoming earnings date is currently scheduled for KROS. This page updates as the calendar is published.
KROS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | -1.21 USD | -0.92 USD | -31.5% | Miss |
| 2026-03-04 | -0.86 USD | -0.49 USD | -75.5% | Miss |
| 2025-02-26 | -1.14 USD | -1.36 USD | +16.2% | Beat |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
KROS valuation and analyst view
| Trailing P/E | -4.18 |
|---|---|
| Trailing EPS | -2.28754 USD |
| Price / book | 1.33 |
| Dividend yield | 0.00% |
| Market cap | 0.33B |
| Analyst consensus | Buy (9 buy / 7 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Keros Therapeutics (KROS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for KROS. This page updates as the calendar is published.
Did KROS beat earnings last quarter?
In its 2026-05-14 report, KROS posted EPS of -1.21 USD versus a -0.92 USD estimate — a miss of 31.5%.
What is KROS's earnings track record?
Over the last 3 reported quarters with consensus data, KROS beat estimates 1 times (33%).
What is KROS's current P/E ratio and EPS?
KROS trades at a trailing P/E of -4.18 on trailing EPS of -2.2875397579084678 USD.
What do analysts rate KROS?
Analyst consensus is "Buy" across 16 ratings (0 strong buy, 9 buy, 7 hold, 0 sell, 0 strong sell).